Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection

Sander G Kuiper*, Anneke C Dijkmans, Erik B Wilms, Ingrid M C Kamerling, Jacobus Burggraaf, Jasper Stevens, Cees van Nieuwkoop

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: To evaluate the pharmacokinetics and clinical effectiveness of IV and oral fosfomycin treatment in patients with recurrent urinary tract infection (rUTI) with Escherichia coli.

Patients and methods: Patients with rUTI treated with 3 g of oral fosfomycin every 72 h for at Least 14 days were included in a prospective open-Label single-centre study. Serum samples were taken after oral and IV administration of fosfomycin. Urine was collected for 24 h on 3 consecutive days. Fosfomycin concentrations in serum and urine were analysed using validated LC-MS/MS. Pharmacokinetics were evaluated using a population model. EudraCT number 2018-000616-25.

Results: Twelve patients were included, of whom nine were also administered IV fosfomycin. Data were best described by a two-compartment model with Linear elimination and a transit-absorption compartment. Median values for absolute bioavailability and serum half-Life were 18% and 2.13 h, respectively. Geometric mean urine concentrations on Days 1, 2 and 3 were above an MIC of 8 mg/L after both oral and IV administration. Quality of Life reported on a scale of 1-10 increased from 5.1 to 7.4 (P= 0.001). The average score of UTI symptoms decreased after fosfomycin dosing (by 3.1 points, 95% CI = -0.7 to 7.0, P= 0.10).

Conclusions: Oral fosfomycin at 3 g every 72 h provides plasma and urine concentrations of fosfomycin above the MIC for E. coli. This pharmacokinetic model can be used to develop optimal dosing regimens of fosfomycin in patients with UTI.

Original languageEnglish
Pages (from-to)3278-3285
Number of pages8
JournalJournal of Antimicrobial Chemotherapy
Volume75
Issue number11
Early online date26-Jul-2020
DOIs
Publication statusPublished - Nov-2020

Keywords

  • LC-MS/MS METHOD
  • FEMALE-PATIENTS
  • TROMETAMOL
  • PHARMACODYNAMICS
  • PENETRATION
  • ABSORPTION
  • PROFILE
  • PLASMA

Cite this